Major Health NewsHealth, biotech and life sciences releases

Health & Medical · Week of Nov 9, 2026

Lilly reports Taltz-Zepbound data, InMode posts Q3: health releases

InMode, American Shared Hospital Services, PAVmed and Zhengye posted results; ComplexCare refinanced, Aflac raised its dividend and IceCure added a patent.

· Major Health News newsroom

Earnings dominated the week. InMode reported third quarter GAAP revenues of $92.1 million and reaffirmed its 2026 outlook, while American Shared Hospital Services posted a 6.3% revenue rise alongside a wider net loss. PAVmed reported preliminary results and said its Lucid Diagnostics unit began receiving Medicare payments for EsoGuard in October. Zhengye Biotechnology reported lower first-half revenue but a narrower loss.

Outside earnings, Eli Lilly and Company presented 52-week Phase 3b data on Taltz used with Zepbound in adults with psoriatic arthritis and obesity or overweight. On the capital side, ComplexCare Solutions refinanced its credit facilities and Aflac Incorporated raised its quarterly dividend. IceCure Medical added a patent in China following its September 2026 marketing approval there.

  1. American Shared Hospital Services

    American Shared Hospital Services Reports Third Quarter and Nine-Month 2026 Financial Results

    American Shared Hospital Services said third quarter revenue rose 6.3% to $7.6 million while net loss attributable to the company widened to $620,000, or $0.09 per diluted share, from $17,000 a year earlier. The company expects patient treatments at its Guadalajara joint venture with Hospital San Javier to begin in mid-2027 after a Gamma Knife Esprit upgrade.

  2. Zhengye Biotechnology Holding Limited

    Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026

    Zhengye Biotechnology Holding Limited reported six-month net revenue of RMB50.9 million, down 18.3%, with swine vaccine revenue falling to RMB38.2 million, while net loss narrowed to RMB22.2 million. Cash fell to RMB31.9 million as of June 30, 2026, and the company attributes the revenue decline to customer cost-cutting.

  3. InMode Ltd.

    InMode Reports Third Quarter 2026 Financial Results: Quarterly GAAP Revenues of $92.1 Million; Reaffirms Full-Year 2026 Financial Outlook

    InMode Ltd. reported third quarter GAAP revenues of $92.1 million, versus $93.2 million a year earlier, and GAAP net income of $18.9 million, and reaffirmed 2026 revenue guidance of $365 million to $375 million. The company says GAAP operating margin fell to 19% from 22%, mainly due to a North American sales team restructuring, and that it will resume investor relations activities after its Special Committee completed its work.

  4. PAVmed Inc.

    PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results

    PAVmed Inc. said Lucid Diagnostics performed 2,871 EsoGuard tests and recognized $1.2 million in revenue in 3Q26, began receiving Medicare payments in October, and says October was a record month with more than 1,800 tests. Veris Health reached design freeze on its implantable monitor ahead of a planned early 2027 FDA 510(k) submission, while PAVmed held $8.9 million in cash, including $5.3 million restricted.

  5. ComplexCare Solutions

    ComplexCare Solutions Closes Refinancing with Regions Bank and Pinnacle Bank, Lowering Cost of Capital and Enabling Long-term Growth

    ComplexCare Solutions, a Vesey Street Capital Partners portfolio company, closed a refinancing with Regions Bank and Pinnacle Bank consisting of a revolving credit facility and a Term Loan A that repaid its existing term loan in full. The company says the deal lowers its interest rate and extends its debt maturity to 2031.

  6. Aflac Incorporated

    Aflac Incorporated Announces 4.9% Increase in the First Quarter 2027 Dividend

    Aflac Incorporated declared a first quarter 2027 dividend of $0.64 per share, a 4.9% increase, payable March 1, 2027, to shareholders of record on February 17, 2027. Chairman and CEO Daniel P. Amos cited 44 consecutive years of dividend increases.

  7. IceCure Medical

    IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio

    IceCure Medical said China's National Intellectual Property Administration granted it a patent covering a connector used in its cryogenic technology platform, bringing its portfolio to 42 patents across the United States, Europe, Great Britain, China and Japan. The grant follows the September 2026 approval from China's National Medical Products Administration to market ProSense and its cryoprobes in China.

This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Major Health News reporting.